Navigation Links
Vanda Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 10, 2009
Date:8/6/2009

ROCKVILLE, Md., Aug. 6 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders, today announced it will release results for the quarter ended June 30, 2009, on Monday, August 10, 2009, before the market opens. A full text copy of the release will be disseminated at that time.

Mihael H. Polymeropoulos, M.D., President and Chief Executive Officer, will host a conference call to discuss the results at 10:00 AM ET on Monday, August 10, 2009. Also participating on the call will be Stephanie R. Irish, Acting CFO. To participate in the conference call, dial the appropriate number below shortly before the 10:00 AM start time and ask for the Vanda Pharmaceuticals conference call hosted by Dr. Polymeropoulos.

    The teleconference dial-in numbers are as follows:
    Domestic callers 1-800-599-9829
    International callers 1-617-847-8703
    Participant Passcode 93125446

The conference call will be broadcast simultaneously and archived on the Company's Web site, www.vandapharma.com. Investors should go to the Web site at least 15 minutes early to register, download, and install any necessary audio software.

A replay of the call will be available on Monday, August 10, beginning at 1:00 PM ET and will be accessible until Monday, August 17, 2009, at 5:00 PM ET. The replay call-in number is 1-888-286-8010 for domestic callers and 1-617-801-6888 for international callers. The access number is 78449791.

ABOUT VANDA PHARMACEUTICALS INC.:

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. For more on Vanda Pharmaceuticals Inc., please visit http://www.vandapharma.com.


'/>"/>
SOURCE Vanda Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Vanda Pharmaceuticals to Present Data on Fanapt(TM) and Tasimelteon at the 162nd American Psychiatric Association Annual Meeting
2. Vanda Pharmaceuticals Reports First Quarter 2009 Results
3. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results
4. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
5. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
6. Vanda Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008
7. LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests
8. Vanda Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
9. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
10. Data Published in Cell Stem Cell Demonstrates Potent Anti-Cancer Activity for OncoMed Pharmaceuticals Lead Antibody
11. Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ... May 04, 2016 , ... Proove Biosciences, Inc. , ... strategic partnership with McGill University . The partnership is designed to advance research ... order to help patients in pain. With the new agreement, researchers at Proove Biosciences ...
(Date:5/4/2016)... ... May 04, 2016 , ... PBI-Gordon Corporation is pleased ... Sales. , Doug began his career at PBI-Gordon in February 1988, after finishing ... wide variety of roles, ranging from customer service to national product manager, to helping ...
(Date:5/3/2016)... ... , ... In a list published by the Boston Business Journal, iLab ... a small percentage of the state's 615,000+ small businesses. The list examined companies based ... from 2012 to 2015. , As this award comes on the heels ...
(Date:5/3/2016)... ... May 03, 2016 , ... Wearable ... and data driven conferences, will take place on June 7-8, 2016, at the New York ... Raman-Tangella on incorporating technology -- including AR/VR, machine learning, apps, robotics and AI -- ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
(Date:4/15/2016)... , April 15, 2016 ... "Global Gait Biometrics Market 2016-2020,"  report to their ... ) , ,The global gait biometrics market ... 13.98% during the period 2016-2020. Gait ... which can be used to compute factors that ...
(Date:3/29/2016)... LegacyXChange, Inc. (OTC: LEGX ... Protect are pleased to announce our successful effort to ... of writing instruments, ensuring athletes signatures against counterfeiting and ... athletes on LegacyXChange will be assured of ongoing proof ... Bill Bollander , CEO states, "By inserting ...
Breaking Biology News(10 mins):